Angiotensin Converting Enzyme 2 News and Research

RSS

Trail of research that led to discovery of aspirin's role in prevention of first heart attack

Charles H. Hennekens, M.D., DrPH, the first Sir Richard Doll Research Professor as well as first recipient of an endowed chair in the new Charles E. Schmidt College of Medicine at Florida Atlantic University, has published a Citation Classic in the current issue of Clinical Chemistry. Hennekens was the founding principal investigator (PI) of the landmark Physician's Health Study and was the first to demonstrate that aspirin prevents a first heart attack.

7 Jan 2012

GSK initiates rhACE2 phase IIa study for Acute Lung Injury

APEIRON Biologics AG announced today that GlaxoSmithKline, exclusive, worldwide licensee for Apeiron's new investigational recombinant human Angiotensin Converting Enzyme 2 (rhACE2, name: GSK2586881, formerly APN01), has initiated a phase IIa study in patients suffering from Acute Lung Injury.

19 Dec 2011

ACE inhibitors, ARBs have different effects on heart health of dialysis patients

Two seemingly similar blood pressure-lowering drugs have different effects on the heart health of dialysis patients, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.

12 Dec 2011

Combination of antipsychotic and antidepressant drugs may increase risk of CV mortality

People taking anti-psychotic drugs and anti-depressant drugs have a much higher risk of dying during an acute coronary event of a fatal arrhythmia than the rest of the population, finds a Finnish study published in the European Heart Journal.

16 Nov 2011

Eliminating drug co-pays improves medication adherence in heart attack patients

The use of specific medications following a heart attack has been shown to reduce cardiovascular events and mortality, however; while highly effective, the rate of adherence to these medications is poor. Researchers from Brigham and Women's Hospital (BWH) evaluated whether eliminating co-payments for these medications would increase adherence and improve outcomes in patients who have had a heart attack.

15 Nov 2011

No unique link between first-trimester ACE inhibitor use and birth defects

Women who take angiotensin-converting enzyme (ACE) inhibitors to treat high blood pressure in the first trimester of their pregnancies are at no greater risk of having babies with birth defects than are women who take other types of high blood pressure medication or who take no blood pressure drugs, according to a new study from the U.S. Department of Health and Human Services' (HHS) Agency for Healthcare Research and Quality.

21 Oct 2011

ESC to deliver educational programme on cardiovascular disease in Beijing

At over 40%, the mortality rate due to cardiovascular disease (CVD) in China is amongst the highest in the world- and has been rightly described as an epidemic. Its population faces a catalogue of CVD risk factor statistics that expose high levels of obesity, diabetes, cholesterol and blood pressure, and a smoking habit within males that is proving stubborn to address.

13 Oct 2011

AHRQ's new Spanish-language guide on heart medications

A free, illustrated easy-to-read pamphlet that compares drugs for preventing heart attacks, heart failure or strokes in people with stable coronary heart disease is one of six new Spanish-language publications from HHS' Agency for Healthcare Research and Quality that help patients compare treatments for common illnesses.

16 Aug 2011

Dyax initiates ecallantide Phase 2 trial for ACE inhibitor-induced angioedema

Dyax Corp. announced today treatment of the first patient in a Phase 2 trial evaluating the efficacy and safety of ecallantide, a potent, selective, reversible inhibitor of plasma kallikrein, for acute treatment of angiotensin converting enzyme (ACE) inhibitor-induced angioedema.

4 Aug 2011

Patient-centered medical home boosts diabetes outcomes, health

A health-care delivery model called patient-centered medical home (PCMH) increased the percentage of diabetes patients who achieved goals that reduced their sickness and death rates, according to health researchers.

14 Jul 2011

Key heart failure therapies could prevent nearly 68,000 deaths each year

A national study has found that nearly 68,000 deaths potentially could be prevented each year by optimally implementing key national guideline-recommended therapies, including critical medications and cardiac devices, for all eligible heart failure patients.

7 Jun 2011

Ramipril can effectively reduce risk of ESRD in obese patients

The angiotensin-converting enzyme inhibitor drug, ramipril, is particularly effective in lowering the risk of end-stage renal disease in obese patients, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology.

29 Apr 2011

ACC/AHA release consensus document to help clinicians reduce risk of hypertension in older adults

Hypertension is very common among older adults. 64 percent of older men and 78 percent of older women have high blood pressure, placing them at heightened risk for heart disease including heart failure, stroke, coronary artery disease and atrial fibrillation, as well as chronic kidney disease and diabetes mellitus.

26 Apr 2011

Adherence to guideline-related therapies can reduce heart failure patients' mortality rate

A UCLA-led study has found that adherence to national guideline-recommended therapies for heart failure in an outpatient practice setting significantly lowered the mortality rate of heart failure patients.

5 Apr 2011

Singing reduces blood pressure prior to total knee replacement surgery

Doctors report that singing reduced the blood pressure of a 76-year-old woman who had experienced severe preoperative hypertension prior to total knee replacement surgery for osteoarthritis (OA). While the patient was unresponsive to aggressive pharmacologic interventions, the woman's blood pressure dropped dramatically when she sang several religious songs.

30 Mar 2011

Concert initiates CTP-499 Phase 1 study in patients with diabetic nephropathy

Concert Pharmaceuticals, Inc. today announced it has made significant progress advancing CTP-499, its novel anti-inflammatory, anti-oxidant, and anti-fibrotic agent for diabetic nephropathy and other forms of chronic kidney disease, into clinical development.

29 Mar 2011

ACE, ARB combination therapy may increase risk of kidney failure, death

Elderly patients prescribed combination angiotensin converting enzyme inhibitors and angiotensin receptor blockers had a higher risk of kidney failure and death, according to a study published in CMAJ.

22 Mar 2011

Apeiron in antitumor substances deal with Cleveland Clinic

APEIRON Biologics AG announced that it has entered into an exclusive option to license from the Cleveland Clinic a number of novel compounds. These compounds are currently in development at Cleveland Clinic as drug candidates for treatment of various cancers, designed to fight cancer based on stimulation of the immune system. In preclinical models, they have shown anti-cancer activity and a favourable toxicity profile as orally available agents.

15 Mar 2011

IQWiG publishes results of search update for evidence-based clinical practice guidelines on CHD

On 7 February 2011, the German Institute for Quality and Efficiency in Health Care published the results of a search update for evidence-based clinical practice guidelines on coronary heart disease.

17 Feb 2011

Older adults with recent heart attack, kidney dysfunction lack long-term medication adherence: Study

Among older adults with a recent heart attack, those with lower levels of kidney function are less likely to take their medications as prescribed, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology.

14 Jan 2011